期刊
EUROPEAN JOURNAL OF CANCER
卷 43, 期 6, 页码 974-978出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2007.01.018
关键词
imatimb; cardiotoxicity; GIST
类别
资金
- NCI NIH HHS [5U10 CA11488-32, 5U10 CA11488-33, 2U10 CA11488-29, 5U10 CA11488-31, 5U10 CA11488-30, 5U10 CA11488-34] Funding Source: Medline
Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity. (C) 2007 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据